Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects.
Investment fund Pharma Connect Capital (PCC), established on 10 October 2017, invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects. In doing so, PCC contributes to closing the innovation and financing gap that emerged in recent years now that the pharmaceutical industry is delegating more and more tasks.
PCC is professionally managed by Jan Hendriks (CEO Innocore Pharmaceuticals, former board member of Ing. G.J. Smid fund and former CEO of Pharma-Bio Research). This experienced entrepreneur comes from the dynamic environment of Groningen, where a wide variety of Life Sciences companies together form a solid and unique cluster of activities. Together with the University Medical Center Groningen and the University of Groningen, they form the lifeblood of this industry in the region. Hendriks provides PCC with a large network of national and international contacts. The fund works closely together with the Pharma Portal. Groningen shows its ambition with the Pharma Connect Capital fund.
